** Shares of drug developer Viking Therapeutics rise 2.5% to $66.68
** Co reports Q1 loss of 26 cents/shr vs analysts' average loss estimate of 28 cents/shr - LSEG data
** In March, co's experimental tablet reduced weight by as much as 3.3% when tested in volunteers enrolled in a small early-stage trial
** "VKTX is now a fairly de-risked biotech operating in one of, if not the most, exciting space in biotech, obesity" said Truist analyst Joon Lee
** Including session's move, stock has more than doubled YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments